Cambrex Corp. engages in the provision of products, services, and technologies to accelerate and improve the development and commercialization of new and generic therapeutics. It supplies to innovator and generic pharmaceutical companies. Its products include generic and branded APIs, controlled substances, chiral compounds, high potency APIs, and advanced intermediates. The company was founded by Arthur Mendolia and Cyril C. Baldwin Jr. in December 1981 and is headquartered in East Rutherford, NJ.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryLife Sciences Tools & Services
SectorMedical
Phone201-804-3000
Debt
Current Ratio4.54
Quick Ratio3.41
Price-To-Earnings
Sales & Book Value
Annual Sales$534.46 million
Price / Sales2.68
Price / Cash Flow11.10
Price / Book2.57
Profitability
Net Income$102.45 million
Net Margins22.67%
Return on Assets14.86%
Miscellaneous
Employees1,228
OptionableOptionable
Cambrex (NYSE:CBM) Frequently Asked Questions
What is Cambrex's stock symbol?
Cambrex trades on the New York Stock Exchange (NYSE) under the ticker symbol "CBM."
How were Cambrex's earnings last quarter?
Cambrex Co. (NYSE:CBM) announced its quarterly earnings data on Thursday, November, 8th. The biotechnology company reported $0.49 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.59 by $0.10. The biotechnology company earned $104.62 million during the quarter, compared to analyst estimates of $122.04 million. Cambrex had a net margin of 22.67% and a return on equity of 22.20%. The firm's revenue was down 7.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.55 earnings per share. View Cambrex's Earnings History.
When is Cambrex's next earnings date?
What guidance has Cambrex issued on next quarter's earnings?
Cambrex updated its FY 2018 earnings guidance on Thursday, November, 8th. The company provided earnings per share guidance of $2.95-3.09 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.79.
What price target have analysts set for CBM?
5 analysts have issued 1-year price objectives for Cambrex's stock. Their predictions range from $63.00 to $75.50. On average, they anticipate Cambrex's share price to reach $69.25 in the next twelve months. This suggests a possible upside of 62.0% from the stock's current price. View Analyst Price Targets for Cambrex.
What is the consensus analysts' recommendation for Cambrex?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cambrex in the last year. There are currently 1 hold rating, 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cambrex.
Has Cambrex been receiving favorable news coverage?
News headlines about CBM stock have trended somewhat positive this week, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cambrex earned a coverage optimism score of 1.9 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future.
Who are some of Cambrex's key competitors?
Some companies that are related to Cambrex include Perrigo (PRGO), Dr.Reddy's Laboratories (RDY), SAGE Therapeutics (SAGE), Amarin (AMRN), GALAPAGOS NV/S (GLPG), Alkermes (ALKS), United Therapeutics (UTHR), Catalent (CTLT), TESARO (TSRO), FibroGen (FGEN), Amneal Pharmaceuticals (AMRX), GW Pharmaceuticals PLC- (GWPH), Array Biopharma (ARRY), Taro Pharmaceutical Industries (TARO) and Horizon Pharma (HZNP).
Who are Cambrex's key executives?
Cambrex's management team includes the folowing people:
- Steven M. Klosk, President, Chief Executive Officer & Director
- Shawn P. Cavanagh, Chief Operating Officer & Executive Vice President
- Gregory P. Sargen, Chief Financial Officer
- James G. Farrell, Vice President & Controller
- Samantha M. Hanley, Secretary, Vice President & General Counsel
Who are Cambrex's major shareholders?
Cambrex's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Copper Rock Capital Partners LLC (1.17%), Summit Creek Advisors LLC (0.68%), Confluence Investment Management LLC (0.28%), Scout Investments Inc. (0.27%), IMA Wealth Inc. (0.10%) and Louisiana State Employees Retirement System (0.04%). Company insiders that own Cambrex stock include Gregory Sargen, Ilan Kaufthal, Leon J Hendrix Jr, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Institutional Ownership Trends for Cambrex.
Which institutional investors are selling Cambrex stock?
CBM stock was sold by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Louisiana State Employees Retirement System, Confluence Investment Management LLC, Scout Investments Inc., IMA Wealth Inc. and 6 Meridian. Company insiders that have sold Cambrex company stock in the last year include Gregory Sargen, Ilan Kaufthal, Samantha Hanley, Shawn Cavanagh, Steven M Klosk and Tom George Vadaketh. View Insider Buying and Selling for Cambrex.
Which institutional investors are buying Cambrex stock?
CBM stock was bought by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Fox Run Management L.L.C. and State of Alaska Department of Revenue. View Insider Buying and Selling for Cambrex.
How do I buy shares of Cambrex?
Shares of CBM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cambrex's stock price today?
One share of CBM stock can currently be purchased for approximately $42.75.
How big of a company is Cambrex?
Cambrex has a market capitalization of $1.57 billion and generates $534.46 million in revenue each year. The biotechnology company earns $102.45 million in net income (profit) each year or $3.17 on an earnings per share basis. Cambrex employs 1,228 workers across the globe.
What is Cambrex's official website?
How can I contact Cambrex?
Cambrex's mailing address is ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ, 07073. The biotechnology company can be reached via phone at 201-804-3000 or via email at [email protected]
MarketBeat Community Rating for Cambrex (NYSE CBM)
MarketBeat's community ratings are surveys of what our community members think about Cambrex and other stocks. Vote "Outperform" if you believe CBM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CBM will underperform the S&P 500 over the long term. You may vote once every thirty days.
